Hints and tips:
...But the A class shares trade at $634,030 — meaning a single share is worth four times as much as the average 401(k) plan on Vanguard’s numbers. Sure, no splits means missing out on froth....
...owned company Spectrum Antimicrobials Inc (SAI)....
...The vaccine developed by BioNTech, a German biotechnology company, in partnership with US pharma giant Pfizer, can now be rolled out in the UK under an emergency use authorisation, but the need to keep it...
...It was once a Wall Street darling, executing an inversion deal with Actavis and other aggressive acquisitions. As its growth prospects slowed, investors grew restless....
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Do let us know if you have any idea regarding companies A, D or F (or if we're wrong on the others). Happy hunting....
...Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Allergan received a 10 per cent stake, or 100m shares, in Teva last year after it agreed to sell its generics business Actavis to the Israeli drugmaker last year....
...“And that’s a very different framework for pharma.” Now retired from her job as a registered nurse, Ms Philyaw pays $50 a month for Livongo’s service and lives free of medication....
...Income, Fenner, Standard Life Inv Property Inc Trst, Grafton, F&C UK Real Estate Investments, Cape, Forterra, Custodian REIT, Redrow, Huntsworth, Robert Walters, F&C Private Equity Trust, Headlam, Page,...
...“This is another example of a new wave of highly-targeted treatments, which deliver anticancer drugs even more precisely to where they are needed,” said Dr Gregory Masters, an oncologist at the Helen F Graham...
...That transaction transformed the company, then known as Actavis, from a manufacturer of generic copycat medicines into a branded drugmaker. “Brent is a bold guy,” says one investor....
...But Mr Holford said this seemed unlikely: “The inversion story feels tired now that the Treasury has twice thwarted large-cap pharma deals.”...
...“We would expect Big Pharma’s current level of R&D spending to become a luxury that investors no longer tolerate,” wrote a group of McKinsey consultants in 2011....
...Yet even after a $40bn deal, the pharma sector remains unsettled. Allergan will realise $36bn in cash and shares (after taxes) that it could use for its own dealmaking....
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...Lyrica was initially developed as a treatment for epilepsy but its patent for this use expired last year, allowing Actavis to launch a cut-price version using the medicine’s generic name, pregabalin....
...The battle ended with Allergan securing a huge premium from “white knight” bidder Actavis, the generics pharma company, which paid $70.5bn to buy the company in a deal that closed in March....
...Meanwhile, the $70bn takeover of Allergan by Actavis earlier this year completed the transformation of the company from a maker of low-margin copycat drugs to a leader in profitable “speciality” medicines...
...Chief executive Brent Saunders says the rout in pharma shares could help. “I think over time, if it stays like this, then it should benefit a cash buyer,” he says....
...But Allergan’s combination last year with Actavis — itself newly enlarged through a dizzying series of deals — created a company that fitted his two main criteria....
...In 2012 it was Watson Pharmaceuticals, a generic drugmaker with a market capitalisation of $8bn — a fraction of the $113bn it is worth today....
...It is just over a year since Brent Saunders became chief executive of Allergan, then known as Actavis, but he has changed the company beyond recognition....
...The SM retail group was the first to challenge the Mercury Drug chain, introducing Hutchison Whampoa’s Watsons pharmacy chain stores in its malls in 2002 as part of a JV with the Hong Kong-based investment...
International Edition